ODIN is a new model for collaborative open innovation in science. We believe that many minds are better than one! Therefore, we work hard to unite contributors across the university-industry divide. Our aim is that the open collaborations will help us gain a better understanding of disease at the molecular level, which is essential to accelerate drug discovery. With a starting point in unmet patient needs, ODIN thus funds research projects about biomarkers and target validation.
Funded by Novo Nordisk Foundation, the ODIN project has three years to establish a network of academic and industrial researchers, who can co-create research projects that will help pave the way for better and more efficient drugs and diagnostics in the future.
Our model for open innovation in science builds on two cornerstones:
All research within ODIN occurs at the pre-competitive stages of drug discovery – that is entirely without IP – and because all knowledge and results will be openly shared, the funded ODIN projects will build a strong foundation of basic science knowledge and analytical tools that anyone can access, use or re-purpose. This means that everyone is free to use the results to e.g. develop products that can be commercially protected.
In essence, the ODIN model simplifies the initiation of university-industry collaborations and, by allowing knowledge to be made available to a broader audience, it increases and accelerates potential use.
By removing concerns over IP protection in early stage research, ODIN not only facilitates academic-industry co-creation of projects but also drives open, collective problem-solving and sharing of scientific output.